Menu
← Oncology Approval Tracker
FDA DECISION ·
Nyvepria
pegfilgrastim-apgf · Hospira
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with nonmyeloid cancers receiving myelosuppressive anticancer drugs with a clinically significant risk of febrile neutropenia, to reduce infections manifested by febrile neutropenia.
LAMPGEN ANALYSIS
Why it matters
Added a pegfilgrastim biosimilar for chemotherapy-related infection prevention.
What research teams should watch
Keep administration timing tied to chemotherapy and record the exact biologic dispensed.
PRIMARY RECORDS